ly 293558 has been researched along with Absence Seizure in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Allen, NK; Arnold, MB; Bleisch, T; Borromeo, PS; Leander, JD; Lodge, D; Lugar, CW; Ornstein, PL; Schoepp, DD | 1 |
| Bohme, GA; Boireau, A; Damour, D; Debono, MW; Genevois-Borella, A; Jimonet, P; Mignani, S; Pratt, J; Randle, JC; Ribeill, Y; Stutzmann, JM; Vuilhorgne, M | 1 |
| Bohme, GA; Boireau, A; Bouquerel, J; Damour, D; Debono, MW; Genevois-Borella, A; Hardy, JC; Hubert, P; Jimonet, P; Manfré, F; Mignani, S; Nemecek, P; Pratt, J; Randle, JC; Ribeill, Y; Stutzmann, JM; Vuilhorgne, M | 1 |
| Apland, JP; Aroniadou-Anderjaska, V; Braga, MF; Figueiredo, TH; Rossetti, K | 1 |
| Apland, JP; Aroniadou-Anderjaska, V; Braga, MFM; Figueiredo, TH; Olsen, CH; Prager, EM | 1 |
| Apland, JP; Aroniadou-Anderjaska, V; Braga, MFM; De Araujo Furtado, M; Figueiredo, TH | 1 |
| Almeida-Suhett, CP; Apland, JP; Aroniadou-Anderjaska, V; Braga, MF; Figueiredo, TH; Miller, SL; Prager, EM | 1 |
| Apland, JP; Aroniadou-Anderjaska, V; Braga, MF; Figueiredo, TH; Qashu, F; Souza, AP | 1 |
| Apland, JP; Aroniadou-Anderjaska, V; Braga, MF; Figueiredo, TH; Green, CE; Qashu, F; Swezey, R; Yang, C | 1 |
| Alt, A; Bleakman, D; Calligaro, DO; Gleason, SD; Li, X; Ogden, AM; Weiss, B; Witkin, JM | 1 |
| Fuson, KS; May, PC; Ornstein, PL; Sacaan, AI; Salhoff, CR; Schoepp, DD; Tizzano, JP | 1 |
| Bohme, GA; Boireau, A; Cheve, M; Damour, D; Debono, MW; Genevois-Borella, A; Imperato, A; Jimonet, P; Mignani, S; Pratt, J; Randle, JC; Ribeill, Y; Stutzmann, JM; Vuilhorgne, M | 1 |
12 other study(ies) available for ly 293558 and Absence Seizure
| Article | Year |
|---|---|
Structure-activity studies of 6-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. 2. Effects of distal acid bioisosteric substitution, absolute stereochemical preferences, and in vivo activity.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Carboxylic Acids; Cerebral Cortex; Electroshock; Isoquinolines; Kainic Acid; Mice; Models, Molecular; Molecular Structure; Pipecolic Acids; Rats; Receptors, AMPA; Seizures; Stereoisomerism; Structure-Activity Relationship | 1996 |
Synthesis and potent anticonvulsant activities of 4-oxo-imidazo[1,2-a]inden.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Brain; Cell Membrane; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Routes; Excitatory Amino Acid Agonists; Heterocyclic Compounds, 4 or More Rings; Imidazoles; Inhibitory Concentration 50; Male; Mice; Mice, Inbred DBA; Oocytes; Protein Binding; Pyrazines; Rats; Receptors, AMPA; Seizures; Structure-Activity Relationship; Time Factors; Xenopus | 2000 |
Bioisosteres of 9-carboxymethyl-4-oxo-imidazo[1,2-a]indeno-[1,2-e]pyrazin-2-carboxylic acid derivatives. Progress towards selective, potent in vivo AMPA antagonists with longer durations of action.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Combinatorial Chemistry Techniques; Disease Models, Animal; Excitatory Amino Acid Antagonists; Imidazoles; Inhibitory Concentration 50; Male; Mice; Oocytes; Pyrazinamide; Pyrazines; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Seizures; Structure-Activity Relationship | 2001 |
Delayed tezampanel and caramiphen treatment but not midazolam protects against long-term neuropathology after soman exposure.
Topics: Animals; Anticonvulsants; Brain; Brain Injuries; Female; Male; Midazolam; Nerve Agents; Rats; Seizures; Soman; Status Epilepticus | 2023 |
Susceptibility to Soman Toxicity and Efficacy of LY293558 Against Soman-Induced Seizures and Neuropathology in 10-Month-Old Male Rats.
Topics: Amygdala; Animals; Cholinesterase Inhibitors; Hippocampus; Isoquinolines; Male; Nerve Degeneration; Neuropathology; Rats, Sprague-Dawley; Seizures; Status Epilepticus; Tetrazoles | 2017 |
Full Protection Against Soman-Induced Seizures and Brain Damage by LY293558 and Caramiphen Combination Treatment in Adult Rats.
Topics: Animals; Anticonvulsants; Body Weight; Brain Injuries; Brain Waves; Cholinesterase Inhibitors; Cyclopentanes; Disease Models, Animal; Drug Therapy, Combination; Electroencephalography; Fluoresceins; Fourier Analysis; Isoquinolines; Male; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Seizures; Soman; Tetrazoles; Time Factors | 2018 |
A rat model of nerve agent exposure applicable to the pediatric population: The anticonvulsant efficacies of atropine and GluK1 antagonists.
Topics: Acetylcholinesterase; Animals; Anticonvulsants; Atropine; Chemical Warfare Agents; Cholinesterase Inhibitors; Disease Models, Animal; Hippocampus; Isoquinolines; Male; Nerve Degeneration; Oximes; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, Kainic Acid; Seizures; Soman; Status Epilepticus; Tetrazoles | 2015 |
The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology.
Topics: Animals; Chemical Warfare Agents; Electroencephalography; gamma-Aminobutyric Acid; Interneurons; Isoquinolines; Neurodegenerative Diseases; Neurons; Rats; Receptors, AMPA; Receptors, Kainic Acid; Seizures; Soman; Tetrazoles | 2011 |
Efficacy of the GluK1/AMPA receptor antagonist LY293558 against seizures and neuropathology in a soman-exposure model without pretreatment and its pharmacokinetics after intramuscular administration.
Topics: Animals; Anticonvulsants; Antidotes; Atropine; Brain; Cholinesterase Inhibitors; Electroencephalography; Fluoresceins; Fluorescent Dyes; Injections, Intramuscular; Isoquinolines; Male; Muscarinic Antagonists; Nerve Degeneration; Oximes; Pyridinium Compounds; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Kainic Acid; Seizures; Soman; Tetrazoles; Tissue Fixation | 2013 |
In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders.
Topics: Animals; Anti-Anxiety Agents; Carboxylic Acids; Cells, Cultured; Chlordiazepoxide; Conditioning, Operant; Dose-Response Relationship, Drug; Eating; Humans; In Vitro Techniques; Isoquinolines; Male; N-Methylaspartate; Neurons; Patch-Clamp Techniques; Protein Subunits; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Kainic Acid; Seizures; Tetrazoles | 2006 |
Selective protection against AMPA- and kainate-evoked neurotoxicity by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisoquinoline- 3-carboxylic acid (LY293558) and its racemate (LY215490).
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Cells, Cultured; Excitatory Amino Acid Antagonists; Isoquinolines; Kainic Acid; Male; Mice; Mice, Inbred Strains; Neuroprotective Agents; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Kainic Acid; Seizures; Stereoisomerism; Tetrazoles | 1996 |
8-Methylureido-4,5-dihydro-4-oxo-10H-imidazo[1,2-a]indeno[1,2-e]pyrazines: highly potent in vivo AMPA antagonists.
Topics: Animals; Anticonvulsants; Excitatory Amino Acid Antagonists; Isoquinolines; Mice; Oocytes; Pyrazines; Quinoxalines; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Seizures; Tetrazoles; Xenopus laevis | 2000 |